Cadrenal Therapeutics, Inc. CVKD
1.44 USD +0.07 (+5.11%)
Nov 10, 2026, 12:52 PM EST
1.28 Day range 1.48
0.816 52-week range 13.01
- YTD
- -78.76%
- 1 year
- -87.76%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 203.8% to $3.19 during Tuesday's regular session. The company's market cap stands at $2.6 million. Picard Medical (AMEX:PMI) stock…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million. Aligos Therapeutics (NASDAQ:ALGS)…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Intelligent Bio Solutions (NASDAQ:INBS) stock moved upwards by 8.2% to $2.63 during Tuesday's after-market session. The company's market cap stands at $7.2 million. Jaguar Health…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regular session. The company's market cap stands at $2.7 million. USBC (AMEX:USBC) stock moved upwards by…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. Lakewood-Amedex…
benzinga.com Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket Shares of Pyxis Tankers Inc (NASDAQ:PXS) rose sharply in pre-market trading after the company reported better-than-expected earnings for the second quarter. The company posted quarterly earnings of…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Redhill Biopharma (NASDAQ:RDHL) stock increased by 69.4% to $1.12 during Monday's regular session. The company's market cap stands at $4.0 million. CollPlant Biotechnologies (NASDAQ:CLGN)…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-market session. The market value of their outstanding shares is at $4.0 million. Vivos Therapeutics…
benzinga.com Cadrenal Therapeutics Announces FDA's Feedback At Type D Meeting For CAD-1005 Inhibitor To Treat Heparin-Induced Thrombocytopenia Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced…
benzinga.com Cadrenal Therapeutics Consolidates Multi-Indication Strategy For Cardiac Acute Critical Care Franchise, With Focus On CAD-1005 For Both HIT And CSA-AKI Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes…- benzinga.com Cadrenal Therapeutics Unveils Cardiac Critical Care Franchise, Seeks Partners For Late-Stage Cardiovascular Assets Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditionsCompany is exploring development, licensing, and…
benzinga.com Cadrenal Therapeutics’ Late-Breaking Clinical Data From Phase 2 Study Of 12-LOX Inhibitor CAD-1005 Featured In Oral Presentation At ISTH 2026 Congress Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Seer (NASDAQ:SEER) shares rose 32.1% to $2.14 during Monday's pre-market session. The market value of their outstanding shares is at $89.0 million. Innovative Eyewear (NASDAQ:LUCY) stock rose…
benzinga.com Cadrenal Therapeutics Says Late-Breaking Clinical Data On 12-Lipoxygenase Inhibitor, CAD-1005, Accepted For Oral Presentation At 34th Congress Of ISTH Selection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT)First-ever randomized, blinded, placebo-controlled…
benzinga.com Cadrenal Therapeutics Plans To Submit An FDA Rare Pediatric Disease Designation Request For Tecarfarin As A Treatment For Pediatric Patients With Kawasaki Disease And Coronary Artery Aneurysms Who Need Chronic Oral Anticoagulation Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO International Convention in San DiegoKawasaki…- benzinga.com Cadrenal Therapeutics Plans To Initiate Phase 2a Proof-Of-Concept Clinical Trial Of CAD-1005, Being Studied To Prevent Acute Kidney Injury In High-Risk Patients Undergoing Cardiac Surgery New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussionsAdditional billion-dollar target- Cardiac Surgery-Associated…
- benzinga.com Cadrenal Therapeutics Announces Participation In BIO 2026; To Host Partnering Meetings To Discuss Development And Commercialization Opportunities For Differentiated Pipeline, Headlined By CAD-1005 And Tecarfarin Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential12-LOX…
benzinga.com Cadrenal Therapeutics Q1 EPS $(1.04) Beats $(1.62) Estimate Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.04) per share which beat the analyst consensus estimate of $(1.62) by 35.8 percent. This is a 50.24 percent increase over losses…
benzinga.com Cadrenal Therapeutics Receives FDA Guidance For Phase 3 Trial Of CAD-1005 Heparin-Induced Thrombocytopenia Treatment Cadrenal has completed its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005.The meeting…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Lowers Price Target to $13 HC Wainwright & Co. analyst Joseph Pantginis maintains Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and lowers the price target from $32 to $13.
- benzinga.com Cadrenal Therapeutics Q4 EPS $(1.41) Misses $(1.18) Estimate Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(1.18) by 19.49 percent. This is a 49.64 percent increase over…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Cadrenal Therapeutics Highlights Recent Scientific Findings Demonstrating Potential Of 12-Lipoxygenase Inhibitor, CAD-1005, To Target Inflammatory Consequences Of Obesity And Type 2 Diabetes Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today highlighted recent scientific…
- benzinga.com Cadrenal Therapeutics Data From Phase 2 Trial Of CAD-1005 Demonstrates Reduction In Thrombotic Events Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic disorders, today provided additional perspectives on…
- benzinga.com Cadrenal Therapeutics Announces Data From Phase 2 Study Of CAD-1005 Shows Over 25% Absolute Reduction In Thrombotic Events; CAD-1005 Failed To Significantly Impact Platelet Recovery Rate Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced encouraging results…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150…
- benzinga.com Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results.
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the…
- benzinga.com Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in…
- benzinga.com Martin Midstream Partners And 3 Other Stocks Under $5 Insiders Are Buying The Dow Jones closed lower by around 200 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders…
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 56 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 70 companies achieved new lows for the year.
- benzinga.com Why Progressive Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers
- benzinga.com Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket Gainers Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday.
- benzinga.com Cava Stock Makes A Stand In Mixed IPO Landscape: Where Does It Rank Against Other 2023 Wall Street Debuts? In a year that’s seen a sharp decline in initial public offerings, Washington, D.C.-based Mediterranean restaurant chain Cava Group (NYSE: CAVA) made a striking first public appearance on the New…